Journal
ONCOTARGET
Volume 8, Issue 39, Pages 66504-66515Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16008
Keywords
tType 1 diabetes mellitus; pramlintide; postprandial glucose; adverse events; meta-analysis
Categories
Funding
- National Natural Science Foundation of China [81471054]
- Innovation Project of Guangxi Graduate Education [JGY2015128]
Ask authors/readers for more resources
Aims: We aim to assess the efficacy and safety of pramlintide plus insulin therapy in patients with type 1 diabetes. Methods: We included clinical studies comparing pramlintide plus insulin to placebo plus insulin. Efficacy was reflected by glycemic control and reduction in body weight and insulin use. Safety concerns were hypoglycemia and other adverse events. Subgroup analysis was performed for different doses (30, 60, 90 mu g/meal) and durations (<= 4, 26, 29, >29 weeks) of the treatment. Results: A total of 10 randomized placebo-controlled studies were included for this meta-analysis (pramlintide, n=1978; placebo, n=1319). Compared with controls, patients given pramlintide had significantly lower HbA1c (p < 0.001), total daily insulin dose (p = 0.024), mean mealtime insulin dose (p < 0.001), body weight (p < 0.001) and postprandial glucose level (p = 0.002). The addition of pramlintide increased the incidence of nausea (p < 0.001), vomiting (p < 0.001), anorexia (p < 0.001) and hypoglycemia (p < 0.05) at the initiation of the treatment. The efficacy and adverse reactions of pramlintide were largely significant for the different doses and durations of the treatment. Conclusions: The addition of pramlintide to insulin therapy in patients with type 1 diabetes improves glycemic control and reduces insulin requirement and body weight while bringing transient hypoglycemia and digestive disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available